Denali Ventures pursues unique opportunities with early stage companies having proprietary technology and novel methods for improving the diagnosis, treatment, and management of significant disease entities and medical conditions. 


The management team's unique experience with biotechnology, genetics, pharmaceutical, medical device and other health care technology companies allows Denali Ventures to evaluate your technology efficiently and effectively, and to help you grow your company.



22%- Pharmaceuticals: D-Pharm,Collgard
22%- Computer Medicine & Health: Hyperoll, E&C
12%- BioTech: Gamida Cell
22%- Radiology / Imaging: TransScan, R3
22%- Medical Devices: ESC, ASI

Denali Ventures is particularly interested in companies having innovative platforms which incorporate pharmaceutical, technological and industrial enhancements in a manner that improves the efficiency and effectiveness of medical, surgical and ancillary intervention.

Denali predominantly invests in seed or early stage companies that demonstrate a specific and crucial technological advantage when compared to existing technologies and modalities.

Above all else, Denali spends a great deal of time and effort in trying to fund companies that are founded and managed by people who demonstrate an impeccable track record for ingenuity, perseverance and honesty. 

Denalis investments are generally in the $1- $2 Million dollar range, but Denali often takes a lead role in securing additional funding from our various partners in Israel, Europe, and the United States.

Denali tries to offer its investors the benefit of a well-rounded life Science portfolio. Thus, the managing partners are well-versed in clinical medicine, regulatory pathways, biology and computer medicine. Our portfolio mix shows the spectrum of our investments to date.



   In The News

about_us about_us1 about_us2 contact contact1 contact2 for_the index portfolio thanks